For the millions of adults living with weakened immunity — whether from cancer treatment, organ transplantation, HIV, or autoimmune therapies — respiratory syncytial virus has long posed a disproportionate threat. Until now, clinicians lacked clear, evidence-based direction on whether RSV vaccines developed for the general population would translate into meaningful protection for this vulnerable group. These new IDSA guidelines begin to fill that critical gap.
A multidisciplinary expert panel convened by the Infectious Diseases Society of America conducted a systematic review of evidence published between August 2024 and July 2025, applying the rigorous GRADE framework to assess both benefit and harm signals. The central finding is striking: two test-negative case-control studies enrolling immunocompromised adults found that RSV vaccination was associated with a 70% reduction in RSV-related hospitalizations (95% CI: 66%–73%). Indirect data drawn from older-adult cohorts — a population with overlapping immune vulnerability — pointed to 81% effectiveness against critical illness. Safety analysis across three randomized trials found no meaningful difference in serious adverse events between vaccinated and unvaccinated participants. Guillain-Barré syndrome risk, a signal monitored across all RSV vaccine programs, was quantified at approximately 11 excess cases per million doses. The panel issued a strong recommendation supporting age-appropriate RSV vaccination in immunocompromised adults and adolescents.
This guidance carries meaningful weight in a landscape where immunocompromised patients are frequently excluded from pivotal vaccine trials, leaving practitioners to extrapolate from surrogate populations. The 70% hospitalization reduction is notably robust, approaching effectiveness figures seen in immunocompetent elderly adults. However, key limitations temper enthusiasm: the supporting studies are observational in design, making unmeasured confounding a legitimate concern, and the evidence base remains relatively thin given the heterogeneity of immunocompromised states — transplant recipients, those on B-cell depleting agents, and patients with hematologic malignancies likely differ substantially in vaccine response. This is best characterized as an important, practice-clarifying set of guidelines rather than a paradigm shift, consolidating emerging real-world data into actionable clinical direction ahead of the 2025–2026 respiratory virus season.